StockData
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31

MANGOCEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.28−0.01 (-3.38%)

Close on Oct 19, 2026

Market cap
$4.80M
P/E (TTM)
–
Dividend yield
–

About Mangoceuticals

Services-Misc Health & Allied Services, NEC, SIC 8090

Mangoceuticals, Inc. is a company that develops, markets, and sells men's health and wellness products and services, primarily focusing on telehealth and erectile dysfunction treatments. The company connects consumers with licensed healthcare professionals and partnered pharmacies to provide access to prescription and non-prescription wellness options. Its operations encompass several corporate subsidiaries and regional entities, including MangoRx Mexico and MangoRx UK Limited.

The company operates internationally with business interests and entities extending to Mexico and the United Kingdom. Its principal executive offices and headquarters are located in Dallas, Texas. Mangoceuticals conducts its primary administration and corporate management from its leased office premises within the state of Texas.

Summary of the business section of Mangoceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
MANGOCEUTICALS, INC.
Headquarters
Dallas, TX
Address
15110 Dallas Pkwy, Suite 600 75248
Phone
(833) 626-4679
Industry
Services-Misc Health & Allied Services, NEC
Incorporated in
Texas
Fiscal year ends
December 31
Auditor
Turner, Stone & Company, L.L.P., Dallas, Texas

Stock & identifiers

Ticker
MGRX
Exchange
Nasdaq
IPO date
Mar 22, 2023
Shares outstanding
22M, Aug 13, 2026
Public float
$14.73M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-15 reverse, Nov 14, 2024; 1-for-15 reverse, Oct 16, 2024
SEC CIK
1938046
CUSIP
56270V205
ISIN
US56270V2051
LEI
984500BKBD93A8A67E98
EIN
87-3841292

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jacob D. CohenChief Executive Officer, Director8,500,000
Antonios IsaacPresident, Director60,000
Eugene M. JohnstonCFO120,000
Alex P. HamiltonDirector3,334
Kenny MyersDirector136,667
Lorraine Pamela D'AlessioDirector136,667

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 1, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 15, 2026Late filingNotification of late filing
Mar 31, 2026Late filingNotification of late filing
Feb 6, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 4, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 23, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 25, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 19, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 2, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 25, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 7, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 1, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 22, 2023IPOInitial public offering priced (424B4 prospectus)
Feb 6, 2023ListingRegistration of securities on an exchange (Form 8-A)